Do analysts recommend INAB or ALPS?

IN8bio presently has a consensus price target of $4.00, indicating a potential upside of 212.50%. Given IN8bio's stronger consensus rating and higher possible upside, equities research analysts clearly believe IN8bio is more favorable than ALPS Group Inc Ordinary Share. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score IN8bio 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 ALPS Group Inc Ordinary Share 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is INAB or ALPS more profitable?

ALPS Group Inc Ordinary Share's return on equity of 0.00% beat IN8bio's return on equity. Company Net Margins Return on Equity Return on Assets IN8bio N/A -91.18% -76.93% ALPS Group Inc Ordinary Share N/A N/A N/A

Is INAB or MCRB more profitable?

IN8bio has a net margin of 0.00% compared to Seres Therapeutics' net margin of -1,192.94%. IN8bio's return on equity of -91.18% beat Seres Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets IN8bio N/A -91.18% -76.93% Seres Therapeutics -1,192.94% -114.82% -34.15%

Is ALGS or INAB more profitable?

IN8bio has a net margin of 0.00% compared to Aligos Therapeutics' net margin of -241.01%. IN8bio's return on equity of -91.18% beat Aligos Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Aligos Therapeutics -241.01% -160.72% -92.30% IN8bio N/A -91.18% -76.93%

Which has stronger valuation & earnings, INAB or RADX?

IN8bio has higher earnings, but lower revenue than Radiopharm Theranostics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio IN8bio N/A N/A -$19.44M -$1.62 N/A Radiopharm Theranostics $3.63M 9.71 -$24.83M N/A N/A

Is INAB or RADX more profitable?

Radiopharm Theranostics' return on equity of 0.00% beat IN8bio's return on equity. Company Net Margins Return on Equity Return on Assets IN8bio N/A -91.18% -76.93% Radiopharm Theranostics N/A N/A N/A

Do analysts rate INAB or IZTC?

IN8bio currently has a consensus target price of $4.00, suggesting a potential upside of 212.50%. Given IN8bio's stronger consensus rating and higher probable upside, equities analysts plainly believe IN8bio is more favorable than Invizyne Technologies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score IN8bio 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Invizyne Technologies 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better earnings and valuation, INAB or IZTC?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio IN8bio N/A N/A -$19.44M -$1.62 N/A Invizyne Technologies N/A N/A N/A N/A N/A

Is INAB or IZTC more profitable?

Invizyne Technologies' return on equity of 0.00% beat IN8bio's return on equity. Company Net Margins Return on Equity Return on Assets IN8bio N/A -91.18% -76.93% Invizyne Technologies N/A N/A N/A

IN8bio (INAB) Competitors

$1.28 +0.07 (+5.79%)

As of 04:00 PM Eastern

Compare

INAB vs. ALPS, MCRB, ALGS, RADX, and IZTC

Should you buy IN8bio stock or one of its competitors? IN8bio's main competitors and comparable companies include ALPS Group Inc Ordinary Share (ALPS), Seres Therapeutics (MCRB), Aligos Therapeutics (ALGS), Radiopharm Theranostics (RADX), and Invizyne Technologies (IZTC). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does IN8bio compare to ALPS Group Inc Ordinary Share?

IN8bio (NASDAQ:INAB) and ALPS Group Inc Ordinary Share (NASDAQ:ALPS) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, institutional ownership, valuation, dividends, analyst recommendations, earnings and profitability.

ALPS Group Inc Ordinary Share's return on equity of 0.00% beat IN8bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IN8bio	N/A	-91.18%	-76.93%
ALPS Group Inc Ordinary Share	N/A	N/A	N/A

ALPS Group Inc Ordinary Share has higher revenue and earnings than IN8bio. IN8bio is trading at a lower price-to-earnings ratio than ALPS Group Inc Ordinary Share, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IN8bio	N/A	N/A	-$19.44M	-$1.62	N/A
ALPS Group Inc Ordinary Share	$4.86M	10.96	-$2.01M	$0.33	0.97

IN8bio presently has a consensus price target of $4.00, indicating a potential upside of 212.50%. Given IN8bio's stronger consensus rating and higher possible upside, equities research analysts clearly believe IN8bio is more favorable than ALPS Group Inc Ordinary Share.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IN8bio	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
ALPS Group Inc Ordinary Share	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

92.1% of IN8bio shares are held by institutional investors. Comparatively, 27.9% of ALPS Group Inc Ordinary Share shares are held by institutional investors. 14.5% of IN8bio shares are held by insiders. Comparatively, 25.5% of ALPS Group Inc Ordinary Share shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, IN8bio's average media sentiment score of 0.00 equaled ALPS Group Inc Ordinary Share'saverage media sentiment score.

Company	Overall Sentiment
IN8bio	Neutral
ALPS Group Inc Ordinary Share	Neutral

IN8bio has a beta of 0.24, indicating that its stock price is 76% less volatile than the broader market. Comparatively, ALPS Group Inc Ordinary Share has a beta of -0.1, indicating that its stock price is 110% less volatile than the broader market.

Summary

ALPS Group Inc Ordinary Share beats IN8bio on 7 of the 12 factors compared between the two stocks.

How does IN8bio compare to Seres Therapeutics?

IN8bio (NASDAQ:INAB) and Seres Therapeutics (NASDAQ:MCRB) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, analyst recommendations, risk, valuation and media sentiment.

Seres Therapeutics has higher revenue and earnings than IN8bio. Seres Therapeutics is trading at a lower price-to-earnings ratio than IN8bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IN8bio	N/A	N/A	-$19.44M	-$1.62	N/A
Seres Therapeutics	$790K	58.01	$5.70M	-$2.43	N/A

IN8bio presently has a consensus price target of $4.00, indicating a potential upside of 212.50%. Seres Therapeutics has a consensus price target of $17.00, indicating a potential upside of 272.81%. Given Seres Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Seres Therapeutics is more favorable than IN8bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IN8bio	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Seres Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

92.1% of IN8bio shares are held by institutional investors. Comparatively, 59.3% of Seres Therapeutics shares are held by institutional investors. 14.5% of IN8bio shares are held by insiders. Comparatively, 5.2% of Seres Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, Seres Therapeutics had 5 more articles in the media than IN8bio. MarketBeat recorded 5 mentions for Seres Therapeutics and 0 mentions for IN8bio. IN8bio's average media sentiment score of 0.00 beat Seres Therapeutics' score of -0.80 indicating that IN8bio is being referred to more favorably in the media.

Company	Overall Sentiment
IN8bio	Neutral
Seres Therapeutics	Negative

IN8bio has a beta of 0.24, suggesting that its stock price is 76% less volatile than the broader market. Comparatively, Seres Therapeutics has a beta of 0.2, suggesting that its stock price is 80% less volatile than the broader market.

IN8bio has a net margin of 0.00% compared to Seres Therapeutics' net margin of -1,192.94%. IN8bio's return on equity of -91.18% beat Seres Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IN8bio	N/A	-91.18%	-76.93%
Seres Therapeutics	-1,192.94%	-114.82%	-34.15%

Summary

IN8bio beats Seres Therapeutics on 8 of the 15 factors compared between the two stocks.

How does IN8bio compare to Aligos Therapeutics?

Aligos Therapeutics (NASDAQ:ALGS) and IN8bio (NASDAQ:INAB) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, dividends, media sentiment, valuation and analyst recommendations.

In the previous week, Aligos Therapeutics had 3 more articles in the media than IN8bio. MarketBeat recorded 3 mentions for Aligos Therapeutics and 0 mentions for IN8bio. Aligos Therapeutics' average media sentiment score of 0.58 beat IN8bio's score of 0.00 indicating that Aligos Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Aligos Therapeutics	Positive
IN8bio	Neutral

IN8bio has lower revenue, but higher earnings than Aligos Therapeutics. Aligos Therapeutics is trading at a lower price-to-earnings ratio than IN8bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aligos Therapeutics	$31.52M	1.32	-$24.19M	-$7.30	N/A
IN8bio	N/A	N/A	-$19.44M	-$1.62	N/A

Aligos Therapeutics has a beta of 2.31, indicating that its stock price is 131% more volatile than the broader market. Comparatively, IN8bio has a beta of 0.24, indicating that its stock price is 76% less volatile than the broader market.

IN8bio has a net margin of 0.00% compared to Aligos Therapeutics' net margin of -241.01%. IN8bio's return on equity of -91.18% beat Aligos Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aligos Therapeutics	-241.01%	-160.72%	-92.30%
IN8bio	N/A	-91.18%	-76.93%

Aligos Therapeutics currently has a consensus price target of $38.50, suggesting a potential upside of 477.21%. IN8bio has a consensus price target of $4.00, suggesting a potential upside of 212.50%. Given Aligos Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Aligos Therapeutics is more favorable than IN8bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aligos Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
IN8bio	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

60.4% of Aligos Therapeutics shares are owned by institutional investors. Comparatively, 92.1% of IN8bio shares are owned by institutional investors. 7.8% of Aligos Therapeutics shares are owned by company insiders. Comparatively, 14.5% of IN8bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Aligos Therapeutics and IN8bio tied by winning 8 of the 16 factors compared between the two stocks.

How does IN8bio compare to Radiopharm Theranostics?

IN8bio (NASDAQ:INAB) and Radiopharm Theranostics (NASDAQ:RADX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, profitability, dividends, valuation, earnings, risk and analyst recommendations.

IN8bio has higher earnings, but lower revenue than Radiopharm Theranostics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IN8bio	N/A	N/A	-$19.44M	-$1.62	N/A
Radiopharm Theranostics	$3.63M	9.71	-$24.83M	N/A	N/A

In the previous week, Radiopharm Theranostics had 3 more articles in the media than IN8bio. MarketBeat recorded 3 mentions for Radiopharm Theranostics and 0 mentions for IN8bio. IN8bio's average media sentiment score of 0.00 equaled Radiopharm Theranostics'average media sentiment score.

Company	Overall Sentiment
IN8bio	Neutral
Radiopharm Theranostics	Neutral

IN8bio has a beta of 0.24, indicating that its share price is 76% less volatile than the broader market. Comparatively, Radiopharm Theranostics has a beta of 1.63, indicating that its share price is 63% more volatile than the broader market.

92.1% of IN8bio shares are held by institutional investors. 14.5% of IN8bio shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Radiopharm Theranostics' return on equity of 0.00% beat IN8bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IN8bio	N/A	-91.18%	-76.93%
Radiopharm Theranostics	N/A	N/A	N/A

IN8bio currently has a consensus target price of $4.00, suggesting a potential upside of 212.50%. Radiopharm Theranostics has a consensus target price of $11.00, suggesting a potential upside of 350.82%. Given Radiopharm Theranostics' stronger consensus rating and higher probable upside, analysts clearly believe Radiopharm Theranostics is more favorable than IN8bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IN8bio	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Radiopharm Theranostics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

Radiopharm Theranostics beats IN8bio on 8 of the 11 factors compared between the two stocks.

How does IN8bio compare to Invizyne Technologies?

IN8bio (NASDAQ:INAB) and Invizyne Technologies (NASDAQ:IZTC) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership.

IN8bio currently has a consensus target price of $4.00, suggesting a potential upside of 212.50%. Given IN8bio's stronger consensus rating and higher probable upside, equities analysts plainly believe IN8bio is more favorable than Invizyne Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IN8bio	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Invizyne Technologies	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Invizyne Technologies' return on equity of 0.00% beat IN8bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IN8bio	N/A	-91.18%	-76.93%
Invizyne Technologies	N/A	N/A	N/A

92.1% of IN8bio shares are held by institutional investors. 14.5% of IN8bio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, IN8bio's average media sentiment score of 0.00 equaled Invizyne Technologies'average media sentiment score.

Company	Overall Sentiment
IN8bio	Neutral
Invizyne Technologies	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IN8bio	N/A	N/A	-$19.44M	-$1.62	N/A
Invizyne Technologies	N/A	N/A	N/A	N/A	N/A

Summary

IN8bio beats Invizyne Technologies on 5 of the 7 factors compared between the two stocks.

Get IN8bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

INAB vs. The Competition

Export

Metric	IN8bio	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$12.62M	$3.99B	$7.28B	$12.81B
Dividend Yield	N/A	3.64%	2.54%	10.69%
P/E Ratio	-0.79	11.58	271.52	24.23
Price / Sales	N/A	1,370.64	631.42	91.65
Price / Cash	N/A	103.92	78.13	53.57
Price / Book	0.69	17.94	13.44	6.37
Net Income	-$19.44M	-$12.50M	$3.46B	$347.74M
7 Day Performance	16.36%	3.22%	2.24%	0.08%
1 Month Performance	3.23%	6.53%	5.14%	2.13%
1 Year Performance	-42.86%	59.76%	27.85%	20.64%

IN8bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
INAB IN8bio	2.4419 of 5 stars	$1.28 +5.8%	$4.00 +212.5%	-45.2%	$12.62M	N/A	N/A	20
ALPS ALPS Group Inc Ordinary Share	1.0785 of 5 stars	$0.28 -13.8%	N/A	N/A	$44.93M	$4.86M	0.82	N/A	Gap Up
MCRB Seres Therapeutics	2.3988 of 5 stars	$4.39 -2.8%	$17.00 +287.7%	-74.5%	$43.59M	$790K	N/A	330	News Coverage
ALGS Aligos Therapeutics	2.44 of 5 stars	$6.67 +1.4%	$38.50 +477.6%	-27.2%	$41.62M	$31.52M	N/A	90	News Coverage
RADX Radiopharm Theranostics	2.7871 of 5 stars	$2.71 +1.3%	$11.00 +306.5%	-65.7%	$39.14M	$3.63M	N/A	N/A	News Coverage Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:INAB) was last updated on 8/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

IN8bio (INAB) Competitors

INAB vs. ALPS, MCRB, ALGS, RADX, and IZTC

How does IN8bio compare to ALPS Group Inc Ordinary Share?

Summary

How does IN8bio compare to Seres Therapeutics?

Summary

How does IN8bio compare to Aligos Therapeutics?

Summary

How does IN8bio compare to Radiopharm Theranostics?

Summary

How does IN8bio compare to Invizyne Technologies?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INAB vs. The Competition

IN8bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

IN8bio (INAB) Competitors

INAB vs. ALPS, MCRB, ALGS, RADX, and IZTC

How does IN8bio compare to ALPS Group Inc Ordinary Share?

Is INAB or ALPS more profitable?

Which has stronger earnings and valuation, INAB or ALPS?

Do analysts recommend INAB or ALPS?

Do institutionals & insiders believe in INAB or ALPS?

Does the media prefer INAB or ALPS?

Which has more volatility & risk, INAB or ALPS?

Summary

How does IN8bio compare to Seres Therapeutics?

Which has better earnings and valuation, INAB or MCRB?

Do analysts rate INAB or MCRB?

Do insiders and institutionals believe in INAB or MCRB?

Does the media prefer INAB or MCRB?

Which has more risk and volatility, INAB or MCRB?

Is INAB or MCRB more profitable?

Summary

How does IN8bio compare to Aligos Therapeutics?

Does the media refer more to ALGS or INAB?

Which has better valuation & earnings, ALGS or INAB?

Which has more volatility & risk, ALGS or INAB?

Is ALGS or INAB more profitable?

Do analysts recommend ALGS or INAB?

Do institutionals and insiders have more ownership in ALGS or INAB?

Summary

How does IN8bio compare to Radiopharm Theranostics?

Which has stronger valuation & earnings, INAB or RADX?

Does the media refer more to INAB or RADX?

Which has more volatility & risk, INAB or RADX?

Do insiders and institutionals have more ownership in INAB or RADX?

Is INAB or RADX more profitable?

Do analysts recommend INAB or RADX?

Summary

How does IN8bio compare to Invizyne Technologies?

Do analysts rate INAB or IZTC?

Is INAB or IZTC more profitable?

Do insiders & institutionals hold more shares of INAB or IZTC?

Does the media favor INAB or IZTC?

Which has better earnings and valuation, INAB or IZTC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INAB vs. The Competition

IN8bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools